- Home
- NXN vs CALC Comparison
NXN vs CALC Comparison
Compare NXN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXN
- CALC
- Stock Information
- Founded
- NXN 1992
- CALC 2011
- Country
- NXN United States
- CALC United States
- Employees
- NXN N/A
- CALC N/A
- Industry
- NXN Trusts Except Educational Religious and Charitable
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- NXN Finance
- CALC Health Care
- Exchange
- NXN Nasdaq
- CALC Nasdaq
- Market Cap
- NXN 45.3M
- CALC 22.9M
- IPO Year
- NXN N/A
- CALC N/A
- Fundamental
- Price
- NXN $11.54
- CALC $2.13
- Analyst Decision
- NXN
- CALC Strong Buy
- Analyst Count
- NXN 0
- CALC 2
- Target Price
- NXN N/A
- CALC $14.50
- AVG Volume (30 Days)
- NXN 9.7K
- CALC 47.4K
- Earning Date
- NXN 01-01-0001
- CALC 08-11-2025
- Dividend Yield
- NXN 4.23%
- CALC N/A
- EPS Growth
- NXN N/A
- CALC N/A
- EPS
- NXN 0.24
- CALC N/A
- Revenue
- NXN N/A
- CALC N/A
- Revenue This Year
- NXN N/A
- CALC N/A
- Revenue Next Year
- NXN N/A
- CALC N/A
- P/E Ratio
- NXN $48.42
- CALC N/A
- Revenue Growth
- NXN N/A
- CALC N/A
- 52 Week Low
- NXN $10.64
- CALC $1.42
- 52 Week High
- NXN $12.45
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- NXN 49.44
- CALC 48.14
- Support Level
- NXN $11.49
- CALC $1.59
- Resistance Level
- NXN $11.60
- CALC $1.69
- Average True Range (ATR)
- NXN 0.11
- CALC 0.15
- MACD
- NXN -0.00
- CALC 0.01
- Stochastic Oscillator
- NXN 15.38
- CALC 46.51
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.